Annals of Neurology · 1999 · 250 citations · 15 references
Life SciencesNeurologyNeuroscienceDementiaNeurodegenerationNeurogeneticsAlzheimer DiseaseAmyloid FormationDementia BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersPlasma ProteinsAlzheimer Disease DementiaAlzheimer Disease ProgressionAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid Beta PlaquesAmyloid PlaquesLate Onset Alzheimer DiseasePresenilin Mutations
Mutations in the amyloid precursor protein and presenilin 1 and 2 genes result in elevated plasma levels of the amyloid beta-peptide species terminating at amino acid residue 42 (A beta1-42). In a longitudinal study of unrelated elderly individuals, those who subsequently developed Alzheimer's disease had higher plasma levels of A beta1-42 at entry than did those who remained free of dementia. The results indicate that elevated plasma levels of the released A beta peptide A beta1-42 may be detected several years before the onset of symptoms, supporting that extracellular A beta1-42 plays an important role in the pathogenesis of late-onset Alzheimer's disease.
15
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
A New Clinical Scale for the Staging of Dementia
Charles P. Hughes, Leonard van den Berg, Warren L. Danziger et al. · The British Journal of Psychiatry · 1982 · 7K citations
Donalyn Scheuner, Christopher B. Eckman, M. Jensen et al. · Nature Medicine · 1996 · 2.6K citations